The Manufacturers Life Insurance Company Sells 1,116,528 Shares of Becton, Dickinson and Company $BDX

The Manufacturers Life Insurance Company lessened its stake in Becton, Dickinson and Company (NYSE:BDX) by 81.4% in the 2nd quarter, Holdings Channel.com reports. The firm owned 254,652 shares of the medical instruments supplier’s stock after selling 1,116,528 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Becton, Dickinson and Company were worth $38,536,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of BDX. Larson Financial Group LLC increased its stake in Becton, Dickinson and Company by 1.7% during the 4th quarter. Larson Financial Group LLC now owns 3,230 shares of the medical instruments supplier’s stock valued at $627,000 after purchasing an additional 53 shares in the last quarter. Atlantic Union Bankshares Corp lifted its stake in shares of Becton, Dickinson and Company by 0.9% in the fourth quarter. Atlantic Union Bankshares Corp now owns 6,108 shares of the medical instruments supplier’s stock worth $1,185,000 after buying an additional 57 shares in the last quarter. Elevation Point Wealth Partners LLC grew its holdings in shares of Becton, Dickinson and Company by 3.7% during the second quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier’s stock valued at $256,000 after buying an additional 60 shares during the last quarter. BOK Financial Private Wealth Inc. grew its holdings in shares of Becton, Dickinson and Company by 7.3% during the second quarter. BOK Financial Private Wealth Inc. now owns 1,073 shares of the medical instruments supplier’s stock valued at $162,000 after buying an additional 73 shares during the last quarter. Finally, Keating Financial Advisory Services Inc. increased its position in shares of Becton, Dickinson and Company by 41.6% during the second quarter. Keating Financial Advisory Services Inc. now owns 252 shares of the medical instruments supplier’s stock valued at $38,000 after acquiring an additional 74 shares in the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Stock Up 0.2%

BDX stock opened at $190.22 on Thursday. The company has a market cap of $52.41 billion, a price-to-earnings ratio of 57.30, a P/E/G ratio of 13.38 and a beta of 0.19. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The business’s 50-day moving average is $164.35 and its two-hundred day moving average is $160.49. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $193.07.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The business had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the previous year, the company posted $3.68 EPS. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.2%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is 126.51%.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $20,380,155. This trade represents a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the transaction, the executive vice president owned 14,856 shares in the company, valued at $2,686,559.04. This represents a 14.10% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 11,704 shares of company stock valued at $1,963,618. Insiders own 0.40% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on BDX. TD Cowen upped their price objective on Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a research report on Wednesday, August 5th. Royal Bank Of Canada upped their price target on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a report on Thursday, August 13th. Wells Fargo & Company lifted their price objective on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Jefferies Financial Group restated a “buy” rating and set a $210.00 target price on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Finally, Barclays lifted their price target on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Eight research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $185.67.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.